Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards

Fig. 2

Summary of biomarker genes and therapy options from 41 molecular tumor profiles. The left panel indicates genes that were identified at least four or more times by molecular tumor boards in Heidelberg (dot) and Berlin (triangle) as biomarkers. The right panel shows all recommended therapy options by both MTB. Abbreviations of therapy options, are as follows: ICI, immune checkpoint inhibition; TKI, tyrosine kinase inhibitors; CLDN, claudin-directed therapy; CAR-T, chimeric antigen receptor T-cell; CHEMO, chemotherapy; ASS, acetylsalicylic acid; all other gene names refer to treatment directed against these targets

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us